
Cogint (COGT) Stock Forecast & Price Target
Cogint (COGT) Analyst Ratings
Bulls say
Cogent Biosciences Inc. is positioned for significant growth, particularly in 2025, which may enhance its attractiveness as a merger and acquisition target, driven by the potential success of its key programs APEX and PEAK. The company's probability of approval for bezuclastinib in the second-line gastrointestinal stromal tumors (GIST) has been raised to 90%, indicating a strong likelihood of market entry, while peak penetration rates have also been substantially increased to 35%. Moreover, positive data from the APEX, PEAK, and SUMMIT trials underscore bezuclastinib's potential impact across various malignancies, reinforcing confidence in the company's long-term prospects.
Bears say
Cogent Biosciences is projected to incur a significant net loss of $2.28 per share for the full year 2025, indicating ongoing financial challenges. The company faces multiple risks, including potential negative clinical data, slower-than-expected development timelines, and significant hurdles in obtaining regulatory approvals for its therapies. Additionally, setbacks in both later-stage and earlier-stage clinical trials contribute to concerns over lower-than-expected commercial success and the risk of long-term dilution, raising red flags regarding the company's future financial viability.
This aggregate rating is based on analysts' research of Cogint and is not a guaranteed prediction by Public.com or investment advice.
Cogint (COGT) Analyst Forecast & Price Prediction
Start investing in Cogint (COGT)
Order type
Buy in
Order amount
Est. shares
0 shares